1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Anticoagulants-Competitive Landscape, Market & Pipeline Analysis, Forecasted Market Size 2015-2018

Summary:
DelveInsight Report, “Anticoagulants-Competitive Landscape, Market & Pipeline Analysis, Forecasted Market Size 2015-2018” analyzes that Anticoagulants has lot of future scope and potential in the market. Mostly anticoagulants are being used in Venous Thromboembolism and Atrial Fibrillation. There are 16 anticoagulants in pipeline for venous thromboembolism, Atrial Fibrillation, Acute Coronary Syndrome, Stroke and Myocardial Infarction.
DelveInsight analysis predicts that global VTE therapeutics market was worth USD 4 billion in 2014 and expected to reach USD 5.5 billion by 2018 with a Compound Annual Growth Rate (CAGR) of 8.29%.
DelveInsight analysis forecasts that global Atrial Fibrillation market will reach on its peak value USD 13.28 billion in 2018 from USD 7.86 billion in 2014 with compound annual growth rate (CAGR) of 14%.
The Anticoagulants’ market is expected to decline after 2018 as many anticoagulants are going to be generic.

Scope
- Overview of Anticoagulants, which includes its physiology, pathophysiology, diagnosis and treatment.
- Report has covered the worldwide market of Anticoagulants, information of marketed molecules including patent expiry and detail profiling of Pipeline assets
- Anticoagulants annual sales and forecasted sales of major player still 2018
- Venous Thromboembolism and Atrial Fibrillation annual estimates and forecasts are provided along with historical analysis
- Detailed epidemiology for every region as well as trends in epidemiology and Information of Antidotes for Anticoagulants which are in pipeline
- Pipeline analysis: Comprehensive data split across different phases and emerging trends and therapeutic assessments by molecule type, route and mechanism of action
- DelveInsight Anticoagulant report includes strategic competitor assessment, market characterization, opportunities, barriers, challenges and regulatory hurdles for the Anticoagulants market.
- Analysis of the current and future market competition in the global Anticoagulants drug market. Insightful review of the key industry drivers, restraints and challenges.


Reasons to Buy

- The Anticoagulant report covers complete Market and Pipeline intelligence and understanding over therapeutics development for Anticoagulants
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anticoagulants
- DelveInsight Anti-coagulants report helps to develop business strategies by understanding the trends shaping and driving for Anticoagulants market
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anticoagulants pipeline in-depth
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners to enhance and expand business potential and scope
- Identifying the upcoming leaders in the Anticoagulants market in the coming years.

Table Of Contents

Anticoagulants-Competitive Landscape, Market and Pipeline Analysis, Forecasted Market Size 2015-2018
Table of Contents

Introduction2
Executive Summary7
Blood Coagulation8
Antithrombotic Drugs9
Antiplatelets10
Fibrinolytic Drugs10
Anticoagulants11
Classification of Anticoagulants on the basis of agents11
Active Therapy Areas for Anticoagulants13
Marketed Drugs for Anticoagulants16
List of Marketed drugs with Indication and Approval date17
List of marketed drugs along with Dosage Form and Strength18
Type of Marketed Anticoagulants19
Marketed Anticoagulants Patent Details21
Withdrawal and Discontinued Drugs22
Marketed anticoagulants for each Indication23
Commercial Assessment26
Sales of Major players in Market26
Forecasted Sales of Major players in Market27
Pipeline Drugs for Anticoagulants28
Clinical profile of Phase III pipeline molecules28
Pipeline drugs by Phases30
Pipeline drugs by Mechanism of Action31
Pipeline drugs by Route of Administration32
Pipeline drugs by Molecule Type33
Profile of Pipeline Drugs34
Phase III/ Late Stage Molecules34
Phase II/ Mid Stage Molecules39
Phase I/Early Stage Molecules49
Pre-Clinical Stage Profiles54
Antidotes for Anticoagulants:57
Prevalent Indications for Anticoagulants58
Venous Thromboembolism58
Epidemiology of Venous Thromboembolism58
Trends in epidemiology59
Complications59
Diagnosis of Venous Thromboembolism60
Pathophysiology of Venous Thromboembolism61
Current and future market of Venous Thromboembolism61
Competition and Unmet Need of Venous Thromboembolism market62
Atrial Fibrillation63
Epidemiology of Atrial Fibrillation (AF)63
Diagnosis of Atrial Fibrillation (AF)64
Complications64
Treatment for Atrial Fibrillation65
Prescribing of anticoagulation treatment for atrial Fibrillation in England66
Current and Future Market of Atrial Fibrillation66
Annual cost of treatment for Atrial Fibrillation66
Future Treatment for Atrial Fibrillation67
SWOT Analysis68
Market Research Methodology69
Research Design69
Contact Us71
Disclaimer71

List of Tables
Table 1: Marketed Anticoagulants with Indication and approval date, 2015 17
Table 2: Marketed Anticoagulants with dosage Form and Strength, 2015 18
Table 3: Type of Marketed Anticoagulant drugs , 2015 19
Table 4: Marketed Anticoagulants, Patent Expiry Timeline, 2015 21
Table 5: Withdrawal and Discontinued Drugs, 2015 22
Table 6: Indication wise number of marketed drugs, 2015 23
Table 7: Characteristic of new oral anticoagulants compared with warfarin 24
Table 8: Comparative pharmacology of Warfarin with other drugs 24
Table 9: Choice of anticoagulant based on patient characteristics 24
Table 10: Sales of major players in Market, 2015 26
Table 11: Forecasted Sales of major players in Market, 2015 27
Table 12: Pipeline Anticoagulants, 2015 29
Table 13: Number of Assets in each phase of pipeline, 2015 30
Table 14: Number of pipeline drugs by Mechanism of Action, 2015 31
Table 15: Number of pipeline drugs by Route of Administration, 2015 32
Table 16: Number of pipeline drugs by Molecule Type, 2015 33
Table 17: Current Prescribing of anticoagulation treatment for Atrial Fibrillation in England 66
Table 18: Annual cost of treatment for Atrial Fibrillation 66
Table 19: Future Treatment for Atrial Fibrillation 67


List of Figures
Figure 1: Marketed Anticoagulants, Patent Expiry Timeline, 2015 21
Figure 2: Indication wise number of marketed drugs, 2015 23
Figure 3: Sales of major players in Market, 2015 26
Figure 4: Forecasted Sales of Major players in Market, 2015 27
Figure 5: Number of Assets in each phase of pipeline (%), 2015 30
Figure 6: Number of pipeline drugs by Mechanism of Action (%), 2015 31
Figure 7: Number of pipeline drugs by Route of Administration (%), 2015 32
Figure 8: Number of pipeline drugs by Molecule Type (%), 2015 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Analyze the global market for antithrombotic/anticoagulant drugs and the different segments for treating thrombotic disease. - View competitive analyses of recent developments and ...

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • December 2016
    194 pages
  • Therapy  

    Infectious Dise...  

    Eye Disease  

  • United Kingdom  

View report >

Anti-Infective and Therapy Market in the US - Forecast

  • December 2016
    249 pages
  • Anti-Infective  

    Therapy  

    Hormone  

  • United States  

View report >

Therapy Market in the Netherlands

  • November 2016
    88 pages
  • Therapy  

  • Netherlands  

View report >

Related Market Segments :

Anticoagulant

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.